Skip to search formSkip to main contentSkip to account menu

Durability of the BNT162b2 XBB:1.5-adapted vaccine against JN.1 hospitalisation in Europe, October 2023 to August 2024: A test-negative case-control study using the id.DRIVE platform

Despite the vaccine target not matching the predominant subvariant, BNT162b2 XBB vaccine protected against JN.1-related hospitalisation for up to 30 weeks, and an additional vaccination after six months is warranted to maintain year-round protection.
PDF (opens in a new tab)

406. Effectiveness of the JN.1-adapted BNT162b2 COVID-19 Vaccine in High-Risk Groups against Hospitalization in Europe: A Test-Negative Case-Control using the id.DRIVE Platform

BNT162b2 was effective among adults with specific chronic conditions, including lung disease, cardiovascular disease, hypertension, type 2 diabetes, and obesity, while estimates lacked precision for asthma, chronic liver disease, renal disease, type 1 diabetes, and neurological disorder.
PDF (opens in a new tab)

Durability of the BNT162b2 XBB.1.5-adapted vaccine against JN.1 hospitalisation in Europe, October 2023 to August 2024: A test-negative case-control study using the id.DRIVE platform

Despite the vaccine target not matching the predominant subvariant, BNT162b2 XBB vaccine protected against JN.1-related hospitalization for up to 30 weeks, but protection against hospitalisation was non-significant after 30 weeks since dose, potentially due to further shift in circulating SARS-CoV-2 strains and/or waning immunity.
Publisher (opens in a new tab)

Co-Administration of BNT162b2 COVID-19 and Influenza Vaccines in Adults: A Global Systematic Review

The findings from this review indicate that the co-administration of BNT162B2 with SIVs is both safe and effective, which highlights the value of co-administration, which could enhance vaccine uptake by streamlining immunization protocols and reducing health visits.
PDF (opens in a new tab)

Association between SARS-CoV-2 in wastewater and COVID-19 hospitalizations in three countries, 2022–2024

The association between levels of SARS-CoV-2 in wastewater and COVID-19 hospitalization rates at the national level during and after the pandemic was described and whether wastewater virus level can predict COVID-19 hospitalization rates was explored.
PDF (opens in a new tab)

Correction: Boikos et al. Co-Administration of BNT162b2 COVID-19 and Influenza Vaccines in Adults: A Global Systematic Review. Vaccines 2025, 13, 381

In the original publication [...]
Publisher (opens in a new tab)
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)